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ABSTRACT 
Aim: The aim of this study is to identify the frequency of stroke among severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) cases in Sakarya city, to find out the clinical 
characteristics of patients diagnosed with stroke and to contribute to the national database. 
Material and Methods: This retrospective study was carried out with 783 cases diagnosed 
with SARS-CoV-2 between April-June 2020 at the pandemic hospital in Sakarya city. Patients 
were compared in terms of age, National Institute of Health Stroke Scale (NIHSS), risk factors, 
radiological findings, inpatient treatment, intubation, and mortality rates. 
Results: Out of 26 cases of ischemic stroke, 11 (42.3%) were male and 15 (57.7%) were 
female. In terms of infarction localization, the cause was medial cerebral artery (MCA) in 4 
(15.4%) patients, top of the basilar in 2 (7.7%) patients, basilar artery in 1 (3.8%) patient, 
lacunar in 9 (34.6%) patients and anterior system in 10 (38.5%) patients. There was no 
significant difference in terms of D-dimer and C-reactive protein (CRP) levels according to 
disease severity (both p=0.262). Three (0.38%) patients presented with stroke findings and 
were diagnosed with SARS-CoV-2. Cryptogenic stroke was detected in 8 (30.8%) of the 
SARS-CoV-2 cases. Stroke frequency was calculated as 3.3% among the SARS-CoV-2 cases 
in Sakarya city. 
Conclusion: This is the first study to identify the frequency of stroke among SARS-CoV-2 
patients in Sakarya city and Turkey. Our study is important as it shows that preventing or 
treating ischemic stroke in SARS-CoV-2 cases contributes greatly to the reduction of 
mortality. 







Amaç: Bu çalışmanın amacı Sakarya ilindeki şiddetli akut solunum yolu sendromu 
koronavirüsü 2 (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) olgularında 
inme sıklığını tespit etmek, inme tanısı almış olan hastaların klinik özelliklerini ortaya 
koyabilmek ve ulusal veri tabanına katkıda bulunmaktır. 
Gereç ve Yöntemler: Bu çalışma, Sakarya ilindeki pandemi hastanesinde Nisan-Haziran 2020 
tarihleri arasında SARS-CoV-2 tanısı alan 783 olgu ile geriye dönük olarak yürütüldü. 
Hastalar, yaş, Ulusal Sağlık Enstitüleri İnme Skalası (National Institute of Health Stroke Scale, 
NIHSS), risk faktörleri, radyolojik bulgular, yatarak tedavi, entübe olma durumları ve 
mortalite oranları bakımından karşılaştırıldı. 
Bulgular: Yirmi altı iskemik inmeli olgunun 11 (%42,3)’i erkek ve 15 (%57,7)’i kadın idi. 
Enfarkt lokalizasyonu bakımından 26 hastanın 4 (%15,4)’ü orta serebral arter (medial cerebral 
artery, MCA), 2 (%7,7)’si baziller tepe, 1 (%3,8)’i baziller arter, 9 (%34,6)’u laküner, 10 
(%38,5)’u arka sistemden kaynaklanmaktaydı. D-Dimer ve C-reaktif protein (C-reactive 
protein, CRP) düzeyleri bakımından hastalık şiddetine göre anlamlı bir farklılık yoktu (her iki 
p=0,262). Üç (%0,38) hasta inme bulgusuyla gelip SARS-CoV-2 tanısı almıştı. SARS-CoV-2 
olgularının 8 (%30,8)’inde kriptojenik inme tespit edildi. Sakarya ilinde SARS-CoV-2 
olgularında inme sıklığı %3,3 olarak hesaplandı. 
Sonuç: Bu çalışma SARS-CoV-2 hastalarında inme sıklığını tespit etmeye yönelik Sakarya 
ilinde ve Türkiye’de yapılmış ilk çalışmadır. Çalışmamız, SARS-CoV-2 olgularında iskemik 
inmenin önlenebilmesi ve tedavi edilebilmesinin mortalitenin azalmasına belirgin katkı 
sunduğunu göstermesi bakımından önemlidir. 
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Even though respiratory symptoms are usually focused on 
in severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) cases, we predicted that there may be 
accompanying neurological symptoms due to our 
familiarity  with  the  coronavirus  family.  Stroke  in 
SARS-CoV-2 cases is caused by changes in the body due 
to infection and or the presence of risk factors (1). The 
study that reported the first cases of stroke in Wuhan also 
noted that there were risk factors present in these cases. On 
the other hand, stroke was also reported in young cases 
without any risk factors. This appears to be evidence 
suggesting  that  both  ways  are  possible  (1-3).  Some 
studies on SARS-CoV-2 reported that stroke was much 
more frequent in severe cases with pulmonary 
involvement (4-6). In cases of SARS-CoV-2, the most 
commonly reported condition in the literature has been 
ischemic stroke. Less often, hemorrhagic stroke and sinus 
vein thrombosis have been reported. In SARS-CoV-2 
cases, young cases with stroke along with cases presented 
with only stroke reveal that stroke can also occur at the 
onset of the disease (6-8). The fact that thrombotic 
complications were identified in 31% of the cases despite 
systematic thrombosis prophylaxis shows the importance 
of evaluating patients in intensive care in terms of 
thromboembolism prophylaxis. One of the most important 
markers of this progression is thought to be the D-dimer 
level (9-11). Antithrombotic treatment such as low 
molecular weight heparin and aspirin has been 
recommended for SARS-CoV-2 patients with low D-dimer 
level (11,12). Starting from March 11, 2020, the day when 
the first positive case was detected in Turkey, 
antithrombotic treatment has been a part of the routine 
procedure as per the treatment guidelines of the Ministry 
of Health (13). We think that the reason behind the low 
mortality rates in Turkey could be this prophylactic 
treatment. The objective of our study is to identify the 
frequency of stroke among SARS-CoV-2 cases in Sakarya 
city and to contribute to the national database and 
literature. 
 
MATERIAL AND METHODS 
In this study, 783 cases diagnosed with SARS-CoV-2 at 
the emergency department, wards and intensive care units 
between April 1 and June 15, 2020 at Sakarya Training and 
Research Hospital, which was declared a pandemic 
hospital in March, were retrospectively reviewed. The 
diagnosis was made by evaluating nasopharyngeal swaps 
with polymerase chain reaction (PCR) and thorax 
computed tomography (CT), which presented atypical 
viral pneumonia. The study was approved by the Ethics 
Committee of the Sakarya University Faculty of Medicine 
(27.07.2020, 437) and the General Directorate of Health 
Services of the Ministry of Health. SARS-CoV-2 cases 
over the age of 18, who required neuroimaging due to 
stroke pre-diagnosis, were screened from the hospital 
registration system. Hemorrhagic stroke cases, cases with 
previous stroke history, and cases with missing data were 
excluded from the study. Demographic data, medical 
history, neurological examination result, electrocardiogram 
(ECG), brain CT, diffusion-weighted magnetic resonance 
imaging (MRI), PA chest radiograph, blood biochemistry, 
hemogram  test,  C-reactive protein  (CRP),  D-dimer  and  
 
fibrinogen values of the cases, ischemic stroke diagnosis 
of which was confirmed by clinical and radiological 
sources, were recorded. Known or newly-identified 
accompanying chronic diseases such as cardiac failure, 
arrhythmia, myocardial infarction, diabetes, hypertension, 
chronic obstructive pulmonary disease, pulmonary 
hypertension, pulmonary embolism, and chronic renal 
failure were recorded. Stroke localization was performed 
by evaluating ischemic territories in the brain based on 
brain CT and diffusion-weighted MRI findings. Infarction 
areas were divided into three groups, namely anterior 
cerebral artery (ACA), posterior cerebral artery (PCA) and 
medial cerebral artery (MCA), taking into account arterial 
watershed areas. The National Institute of Health Stroke 
Scale (NIHSS) levels, which determine the severity of the 
disease based on neurological examination of patients, 
were recorded. Those with a NIHSS score of 1 to 8 were 
classified as mild, 9 to 15 as moderate, higher than 16 as 
severe. 
Statistical Analysis 
Statistical analysis was performed by using statistical 
package SPSS v.25.0. Continuous data are described by 
mean±standard deviation (SD) or median interquartile 
range (IQR) and (minimum-maximum), categorical data 
are presented as numbers and percentages. Shapiro-Wilk 
test was used to evaluate the normality assumption for 
numerical variables. In the evaluation of the data, a 
Student's t-test was used for the data with normal 
distribution in order to compare numerical variables, a 
Mann-Whitney U test was used for the data that were not 
normally distributed, and a Pearson Chi-square or Fisher’s 
exact test was used in the analysis of categorical variables. 
Statistical significance was considered as 0.05. 
 
RESULTS 
SARS-CoV-2 patients were showing clinical stroke 
findings and were diagnosed with ischemic stroke with 
neuroimaging. Out of 26 cases of ischemic stroke, 11 
(42.3%) were male and 15 (57.7%) were female. The mean 
age of the patients was 71.7±12.3, the mean age of the male 
patients was 72.0±10.8 and the mean age of the female 
patients was 71.5±12.7 years. Only 2 (7.7%) of the patients 
were 45 years of age and under. Seventeen (65.4%) of the 
patients had a medical history of hypertension, 9 (34.6%) 
patients had diabetes and 3 (11.5%) patients had cardiac 
disease. Nine (34.6%) of the patients were smokers and 1 
(3.8%) patient consumed alcohol. There was no significant 
difference in terms of advanced age, and comorbidities 
according to the disease severity. Demographic 
characteristics and risk factors of patients are shown in 
Table 1. 
In terms of the sub groups of infarction localization, the 
cause was MCA in 4 (15.4%) patients, top of the basilar in 
2 (7.7%) patients, basilar artery in 1 (3.8%) patient, lacunar 
in 9 (34.6%) patients and anterior system in 10 (38.5%) 
patients. In terms of the anatomical localization of lesions 
of ischemic stroke patients, 4 (15.4%) patients had partial 
anterior CI, 13 (50.0%) had posterior CI, 9 (34.6%) had 
lacunar while no patients had total anterior CI. 
Patients were compared in terms of their NIHSS score, 
which was calculated using the NIHSS during admission 
to the clinic, risk factors, radiological localization findings, 




duration of stay at hospital, duration of intubation, and 
mortality rates. In terms of risk factors of the patient group, 
the relationship between age/sex and glucose level at 
arrival, HbA1C, diabetes, hypertension, heart disease, 
smoking and alcohol use was not statistically significant. 
Patients requiring intensive care were grouped under 
severe cases and those followed-up in wards were grouped 
under non-severe cases. Sixteen (61.5%) cases were 
followed-up in intensive care, 10 (38.5%) cases were 
intubated and 8 (30.8%) cases died. CRP and D-dimer 
levels of 26 patients that were included in the study did not 
show a significant difference between severe and non-
severe cases (both p=0.262). There only was a significant 
difference in NIHSS according to the disease severity 
between severe and non-severe cases (p<0.001, Table 2). 
Three (0.38%) patients presented with stroke findings and 
were diagnosed with SARS-CoV-2. Cryptogenic stroke 
was detected in 8 (30.8%) of the SARS-CoV-2 cases. 
Stroke frequency was calculated as 3.3% among the 




Table 1. Clinical characteristics of patients with SARS-CoV-2 
 Total (n=26)  Severe (n=16) Non-severe (n=10) p 
Age (years), mean±SD 71.7±12.3  71.6±14.0 71.4±12.7 0.971 
Age, n (%) 
          <45 













Sex, n (%) 
          Male 













Comorbidities (any), n (%) 8 (28.6)  3 (16.7) 5 (50.0) 0.091 
Hypertension, n (%) 17 (65.4)  8 (50.0) 9 (90.0) 0.087 
Diabetes mellitus, n (%) 9 (34.6)  4 (25.0) 5 (50.0) 0.234 
Cardiac disease, n (%) 3 (11.5)  2 (12.5) 1 (10.0) 0.846 
Smoke, n (%) 9 (34.6)  3 (18.8) 6 (60.0) 0.046 
Alcohol, n (%) 1 (3.8)  0 (0.0) 1 (10.0) 0.385 




Table 2. Laboratory findings of patients with SARS-CoV-2 
 Total (n=26)  Severe (n=16) Non-severe (n=10) p 
C-reactive protein (mg/L) 23.3 (64.2) [1.1-288]  33.2 (59.8) [1.1-288] 7.6 (45.4) [3-231] 0.262 
D-dimer (mg/L) 1505 (2247) [331-29400]  1660 (3652) [373-29400] 1450 (1879) [331-3220] 0.262 
NIHSS 23 (20) [5-39]  27 (12) [23-39] 9 (6) [5-16] <0.001 
Imaging Pattern, n (%) 
          Lacunar 

















First, from Zhongnan Hospital in Wuhan, China, where the 
pandemic first emerged, then, from around the world, as of 
February 7, 2020, neurologists have started to report common 
neurological symptoms including stroke (6,14-16). It has 
been reported that blood coagulation tests (prothrombin 
and D-dimer) of SARS-CoV-2 patients showed abnormal 
results, which increased the possibility of ischemic stroke. 
Initial publications reported stroke in 5% of the cases 
(4,17). Among 388 patients, who applied to a university 
hospital in Italy, 2.5% had ischemic stroke and the mean 
age of these patients was 68.4±5.9 years (18). A study 
involving over 2000 SARS-CoV-2 patients found that the 
rate of cerebrovascular presentations was higher in severe 
cases (19). In our study, we investigated 783 SARS-CoV-2 
positive patients at a pandemic hospital in Sakarya city and 
ischemic stroke was detected in 26 of these cases. Stroke 
frequency was calculated as 3.3% among the SARS-CoV-
2 cases in Sakarya city. 
 
Literature reports that in stroke cases, hypertension, 
diabetes and cardiovascular diseases increase the severity 
of disease (6,14,17,20). Especially in cases where risk 
factors for stroke are present such as hypertension, 
diabetes and smoking, SARS-CoV-2 is much more 
frequent and severe. In our study, only 8 (30.8%) cases 
developed stroke without having any risk factor. In 
cryptogenic cases, transthoracic echocardiogram and 
Doppler ultrasonography of the carotid vertebral artery 
could not be performed due to pandemic restrictions, 
which led to a limitation in determining stroke etiology. 
The age range of SARS-CoV-2 patients with ischemic 
stroke has varied in studies. In a most comprehensive study 
carried out on more than 26 thousand SARS-CoV-2 cases 
in 99 centers, the mean age of ischemic stroke was 71 (6). 
In our study, the age range was in line with the literature. 
Only 2 (7.7%) cases were below the age of 45. 
Subtyping, which is the next step after a stroke diagnosis, is 




of vital importance in predicting prognosis, determining 
discharge and treatment strategies and preventing recurrence. 
In literature, large vascular occlusion has been reported in 
the majority of the cases (6,21). Only 6 (23.1%) of our 
stroke patients had large vascular occlusion. 3 (11.5%) 
cases arrived at the hospital presenting with stroke. Out of 
these, 2 cases actually started having fever and fatigue 
symptoms a few days back but refrained from going to the 
hospital because of the pandemic. Another case applied to 
another hospital presenting with weakness of the left side. 
Upon suspicion at the ER, this case was tested and was 
referred to the pandemic hospital after being diagnosed 
with SARS-CoV-2. 
Literature reports that stroke can also occur at the onset of 
SARS-CoV-2 in cases who only present with stroke 
manifestations without showing any other symptoms such as 
fever, cough and loss of appetite (19). Only one case in our 
study presented with stroke at the onset of SARS-CoV-2. 
SARS-CoV-2 can enter the brain via retrograde neuronal 
or hematogenous propagation (9,17). Due to its direct 
damage on the nervous system and inflammation, hypoxia, 
immobilization and disseminated intravascular 
coagulation it causes, this virus is thought to make people 
susceptible to venous and arterial thromboembolic events. 
Due to the known fact that the disease makes people 
susceptible to thromboembolic events, prophylactic 
antithrombotic treatment is recommended for patients with 
high D-Dimer levels (13,22-24). Twenty three (88.5%) of 
our cases were receiving prophylactic subcutaneous 
heparin and acetylsalicylic acid treatment at two equal 
doses before the diagnosis. CRP and D-dimer levels of our 
stroke cases significantly decreased over time. This 
significant decrease over time is thought to be due to the 
antithrombotic and infection treatment patients were 
receiving. We found a positive correlation between D-
dimer and CRP levels of stroke cases in our study and the 
severity of SARS-CoV-2, and the majority of these cases 
were followed up under intensive care conditions with 
respiratory support. We were not able to find a relationship 
between NIHSS, which is used to identify the severity of 
stroke, and D-dimer and CRP levels. We predict one 
reason for this to be the regular and early administration of 
subcutaneous heparin in all SARS-CoV-2 cases with high 
D-dimer levels. 
In Turkey and all around the world, rigorous and diligent 
efforts are being exerted to prevent death in SARS-CoV-2 
cases. A patient presenting with cerebrovascular event 
findings during the pandemic should be suspected for 
SARS-CoV-2, a detailed medical history should be taken 
and the patient should be tested, if necessary. This is highly 
important both for diagnosing the disease early and for 
preventing the spread of the infection in the hospital and in 
the community. In our study, only 1 case presenting with 
stroke was tested after suspecting SARS-CoV-2 due to a 
routine thorax CT, which then resulted in this case to be 
diagnosed early with SARS-CoV-2. 
The most important limitation of our study was that 
etiological subtyping could not be done in stroke cases. 
Etiology could not be established in cases due to 
pandemic-related restrictions. The cases were only 
compared based on risk factors for stroke. Another 
limitation was that our results only cover moderate and 
severe SARS-CoV-2 cases requiring hospitalization. 
Another limitation was that the association of medication 
used for SARS-CoV-2 with stroke cases could not be 
investigated. As we are facing with a new disease, 
medications used for treatment should also be investigated 
for cerebrovascular side effects. 
 
CONCLUSION 
It could be noted that our study is significant as it will 
contribute to the literature by providing information on 
cerebrovascular events observed in SARS-CoV-2 positive 
cases and will further improve experience on this issue. 
Our study supports the need for patients suffering from 
stroke, even if they are cryptogenic, regardless of the 
etiology of stroke, to be suspected of SARS-CoV-2 during 
the pandemic and for testing suspected cases. 
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